The short version of DMSO stock fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Stupor: absence of psycho-motor activity; not actively relating to the environment Catalepsy: passive induction of a posture held against gravity Waxy flexibility: maintaining positions imposed by the examiner Mutism: minimal or absent verbal response (not due to aphasia) Negativism: resistance or lack of response to instructions or external stimuli Posturing: spontaneous and active maintenance of a posture against gravity Mannerisms: odd or exaggerated caricatures of normal actions Stereotypy: repetitive, abnormally frequent, non-goal-directed movements Agitation: excessive activity not influenced by external stimuli Grimacing: sustained facial expression Echolalia: mimicking another's speech Echopraxia: mimicking another's movements Other disorders (additional code 293.89 [F06.1] to indicate the presence of the co-morbid catatonia):
== Early life and education == Doillon was born on 4 September 1982 in Neuilly-sur-Seine, France. She is the daughter of French writer/director Jacques Doillon and English actress/singer Jane Birkin. She has six brothers and sisters: Kate Barry and Charlotte Gainsbourg on her mother's side, and Lola Doillon, Lili Doillon, Lina Doillon and Lazare Doillon on her father's side. Doillon spent her school years between France and Saint Barthélemy until the age of 15, when she dropped out to become a full-time actress.
Principal cells: columnar cells that, with the basal cells, form the majority of the epithelium. In the caput (head) region, these cells have long stereocilia that are tuft-like extensions that project into the lumen. The stereocilia are much shorter in the cauda (tail) segment. They also secrete carnitine, sialic acid, glycoproteins, and glycerylphosphorylcholine into the lumen. Basal cells: shorter, pyramid-shaped cells, which contact the basal lamina but taper off before their apical surfaces reach the lumen. These are thought to be undifferentiated precursors of principal cells. Apical cells: predominantly found in the head region Clear cells: predominant in the tail region Intraepithelial lymphocytes: distributed throughout the tissue. Intraepithelial macrophages
Sources: en.wikipedia.org
Artificial skin is a collagen scaffold that induces regeneration of skin in mammals such as humans. The term was used in the late 1970s and early 1980s to describe a new treatment for massive burns. It was later discovered that treatment of deep skin wounds in adult animals and humans with this scaffold induces regeneration of the dermis. It has been developed commercially under the name Integra and is used in massively burned patients, during plastic surgery of the skin, and in treatment of chronic skin wounds. Alternatively, the term "artificial skin" sometimes is used to refer to skin-like tissue grown in a laboratory, although this technology is still quite a way away from being viable for use in the medical field. 'Artificial skin' can also refer to flexible semiconductor materials that can sense touch for those with prosthetic limbs (also experimental).
=== 18th century === By the 18th century, the medicinal properties of opium and laudanum were well known, and the term "laudanum" came to refer to any combination of opium and alcohol. In the 18th century several physicians published works about it, including John Jones, who wrote The Mysteries of Opium Revealed (1700), which was described by one commentator as "extraordinary and perfectly unintelligible". The Scottish physician John Brown, creator of the Brunonian system of medicine, recommended opium for what he termed asthenic conditions, but his system was discredited by the time of his death. The most influential work was by George Young, who published a comprehensive medical text entitled Treatise on Opium (1753). Young, an Edinburgh surgeon and physician, wrote this to counter an essay on opium by his contemporary Charles Alston, professor of botany and materia medica at Edinburgh who had recommended the use of opium for a wide variety of conditions. Young countered this by emphasising the risks '...that I may prevent such mischief as I can, I here give it as my sincere opinion... that opium is a poison by which great numbers are daily destroyed.' Young gives a comprehensive account of the indications for the drug including its complications. He is critical about writers whose knowledge of the drug is based on chemical or animal experiments rather than clinical practice. The treatise is a detailed, balanced and valuable guide to prevailing knowledge and practice.
==== Health care ==== Duterte vowed to improve the health care system, certifying the Universal Healthcare Bill as an urgent measure as early as July 2018. In February 2019, he signed the Universal Health Care Act, which automatically enrolls all Filipinos under the government's health insurance program. He also enacted the National Integrated Cancer Control Act which establishes a "national integrated" program to control and prevent cancer by making treatment more accessible and affordable, and the Philippine Mental Health Law, which provides free mental health services down to the barangay level while requiring hospitals to provide psychiatric, psychosocial and neurologic services. In December 2019, Duterte signed a law institutionalizing Malasakit Centers in all hospitals run by the Department of Health, allowing indigent patients to efficiently access financial medical assistance from various government agencies. Duterte ordered the full implementation of the Reproductive Health Law, banned smoking in public places nationwide, and set a price cap on select medicines.
== Products and pipeline == Glenmark's proprietary respiratory drug RYALTRIS, a nasal spray combining an antihistamine and a corticosteroid, received U.S. FDA approval for seasonal allergic rhinitis in adults and adolescents aged 12 and above. The company launched it in the United States in 2022. By 2026 it was available in 55 countries, and in July 2026 the FDA expanded approval to children aged 6 to under 12. The company's oncology portfolio consists mainly of licensed products. It distributes Tevimbra (tislelizumab) and Brukinsa (zanubrutinib) from BeiGene, and markets envafolimab as QiNHAYO in India and selected emerging markets under a license from Jiangsu Alphamab and 3D Medicines. In 2025 Glenmark also licensed trastuzumab rezetecan from Hengrui Pharma and aumolertinib from Hansoh Pharma. In dermatology, Winlevi (clascoterone cream) received European Commission approval for acne treatment in December 2025. Glenmark holds distribution rights in 17 European Union countries. For diabetes, Glenmark launched Lirafit, a liraglutide biosimilar, in January 2024, followed by Glipiq, a semaglutide biosimilar, in March 2026. Glenmark expanded its cardiovascular brand Telma (telmisartan), launched in 2003 for hypertension, to 16 related formulations. By 2024 the brand generated annual revenue of ₹1,036 crore.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.